S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Don’t Let The Markets Break Your Heart (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Don’t Let The Markets Break Your Heart (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Don’t Let The Markets Break Your Heart (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Don’t Let The Markets Break Your Heart (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Don’t Let The Markets Break Your Heart (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
NASDAQ:EVLO

Evelo Biosciences - EVLO Stock Forecast, Price & News

$0.97
0.00 (0.00%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.95
$1.00
50-Day Range
$0.78
$2.21
52-Week Range
$0.74
$4.36
Volume
301,847 shs
Average Volume
181,346 shs
Market Capitalization
$104.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Evelo Biosciences MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
235.1% Upside
$3.25 Price Target
Short Interest
Bearish
4.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Evelo Biosciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$160 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.40) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

811th out of 1,026 stocks

Pharmaceutical Preparations Industry

403rd out of 504 stocks

EVLO stock logo

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

Don’t Let The Markets Break Your Heart
Every rose has its thorn, just like every market has its surprise. If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right, or anticipate massive trend reversals with A.I. pixel
Don’t Let The Markets Break Your Heart
Every rose has its thorn, just like every market has its surprise. If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right, or anticipate massive trend reversals with A.I. pixel
Flagship-backed biotech cuts nearly half its staff
Evelo Biosciences Provides Clinical and Business Updates
Senda Biosciences Announces Close of $123 Million Series C Financing
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings
11/14/2022
Today
2/08/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+235.1%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-122,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.16 per share

Miscellaneous

Free Float
99,138,000
Market Cap
$104.75 million
Optionable
Not Optionable
Beta
1.31

Key Executives

  • Simba Gill
    President, Chief Executive Officer & Director
  • Ann Marella Thorell
    Chief Financial Officer, Treasurer & Senior VP
  • Mark W. Bodmer
    Chief Scientific Officer, President-R&D
  • Andrea Itano
    Senior Vice President & Head-Research
  • Duncan McHale
    Chief Medical Officer













EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings
or view top-rated stocks.

What is Evelo Biosciences' stock price forecast for 2023?

3 brokerages have issued 1 year target prices for Evelo Biosciences' stock. Their EVLO share price forecasts range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.25 in the next year. This suggests a possible upside of 235.1% from the stock's current price.
View analysts price targets for EVLO
or view top-rated stocks among Wall Street analysts.

How have EVLO shares performed in 2023?

Evelo Biosciences' stock was trading at $1.61 at the beginning of the year. Since then, EVLO shares have decreased by 39.8% and is now trading at $0.97.
View the best growth stocks for 2023 here
.

When is Evelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our EVLO earnings forecast
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.05.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Mayo Clinic (0.44%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends
.

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $0.97.

How much money does Evelo Biosciences make?

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $104.75 million. The company earns $-122,180,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Evelo Biosciences have?

The company employs 122 workers across the globe.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 2/9/2023 by MarketBeat.com Staff